id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2000-P-0414-0002,FDA,FDA-2000-P-0414,"Acknowledgment Letter from FDA DDM to Lachman Consultant Services, Inc.",Other,Acknowledgement Letter/Receipt,2017-05-22T04:00:00Z,2017,5,2017-05-22T04:00:00Z,,2017-05-22T13:52:44Z,,0,0,09000064804daf55
FDA-2000-P-0414-0004,FDA,FDA-2000-P-0414,"Answer from FDA CDER to Lachman Consultant Services, Inc.",Other,Answer,2017-05-22T04:00:00Z,2017,5,2017-05-22T04:00:00Z,,2017-05-22T14:10:24Z,,0,0,09000064804daf5d
FDA-2000-P-0414-0003,FDA,FDA-2000-P-0414,Determination That Fluoxetine Hydrochloride 20–Milligram Tablets Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,Notice,Announcement,2017-05-22T04:00:00Z,2017,5,2017-05-22T04:00:00Z,,2017-05-27T19:01:20Z,00-15556,0,0,09000064804daf5b
FDA-2000-P-0414-0001,FDA,FDA-2000-P-0414,"Citizen Petition from Lachman Consultant Services, Inc.",Other,Citizen Petition,2017-05-22T04:00:00Z,2017,5,2000-05-11T04:00:00Z,,2017-05-23T01:00:33Z,,0,0,09000064804daf47